
Development of innovative pharmaceutical technologies to improve patient adherence, treatment accessibility, and reduce environmental impact.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: June 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
MSD France
B
Development of innovative medicines and vaccines to address major public health challenges and improve population health.
Biocodex
B
Development and provision of pharmaceutical solutions focusing on microbiota care, women's health, and orphan diseases.
Chiesi
B
Development and delivery of innovative pharmaceutical products for respiratory, neonatology, transplantation, and rare diseases.
Initiatives identified among leaders
Structuration de la feuille de route et indicateurs pour la mission d’entreprise.
“En 2022, Chiesi a structuré sa feuille de route en...” - ChiesiSensibilisation collaborateurs à la réduction de l’impact environnemental via des experts.
“MSD France met en avant sa priorité de réduire son...” - MSD FranceManifestation d’une philosophie durable centrée sur solidarité, santé et équilibre socio-environnemental.
“Chiesi SAS a publié un manifeste sur le développem...” - Chiesi56% of similar organizations communicate on CSR issues
+753 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports